A standard autologous hematopoietic stem cell transplant (AHSCT) safely and effectively prolongs survival and delays cancer progression in adults with multiple myeloma, a large, real-world international study indicates. Disease relapse was reported in 15.7% in the first year after the transplant, and patients lived a median of 7.5…
Read more
The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has been approved in the European Union as part of a combination treatment for adults with newly diagnosed multiple myeloma who qualify for an autologous hematopoietic stem cell transplant (AHSCT), expanding its number of approved indications in the region. The…
Myeloma is a cancer that forms from a type of white blood cell called B-cells. Learn more about the disease here.
Mutations in critical oncogenes or tumor suppressor genes in B-cells can cause myeloma. Learn more about the causes here.
Symptoms vary from patient to patient and may be mild in the early stages. Learn more about the symptoms here.
Get regular updates to your inbox.
